Physician

Ami Amin, M.D.

According to 2025 Medicare claims, Ami Amin, M.D. (NPI: 1144674219) practices endocrinology in the Camden, NJ market, with the plurality of this provider's patient population coming from Camden, NJ. This provider's primary affiliated billing organization is ADVOCARE, LLC (NPI: 1770538696; TIN: 223537011) and primary practice location at 08016-2250. Amin is affiliated with the Aledade 196 Advocare Collaborative Health MSSP (ACO ID: A5364), participating under the MSSP model.

Amin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 100 traditional Medicare patients, billed 186 HCPCS/CPT codes, and received $12,194 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,460 prescription claims across 265 beneficiaries totaling $737,386 in drug costs, led by Ozempic (Semaglutide). DME data shows 168 claims. Open Payments data shows 10 records totaling $160. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,566 to $737,386. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	49	65	$7,735
2022	231	507	$48,594
2023	242	546	$47,451
2024	100	186	$12,194

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	12	$1,566
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	21	$3,621
2020	63	213	$105,679
2021	111	444	$207,990
2022	258	1,385	$859,638
2023	298	2,147	$1,343,668
2024	265	1,460	$737,386

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	65	162	$21,238
2023	95	382	$52,449
2024	55	168	$56,879

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	92	129	$81
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	11	14	$24
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	27	31	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	94	6,511	$209,647
Trulicity	Dulaglutide	53	3,998	$130,162
Mounjaro	Tirzepatide	57	2,140	$75,892
Jardiance	Empagliflozin	24	2,038	$38,428
Rybelsus	Semaglutide	15	1,170	$35,682

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	25	106	$56,178
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	19	40	$664
A4259	Lancets, per box of 100	N	11	22	$36

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$160	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ami Amin, M.D.?

Tedicare shows public-source Medicare data for Ami Amin, M.D. (NPI 1144674219), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ami Amin, M.D. have ACO affiliation data?

Ami Amin, M.D. is shown with ACO affiliation data for Aledade 196 Advocare Collaborative Health MSSP (MSSP, ACO ID A5364).

What billing organization is linked to Ami Amin, M.D.?

Ami Amin, M.D. is linked to ADVOCARE, LLC (billing NPI 1770538696) in the available physician profile data.

Does Ami Amin, M.D. have Open Payments data?

Ami Amin, M.D. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.